Compare
Annexon, Inc. vs Tonix Pharmaceuticals Holding Corp. vs Contineum Therapeutics, Inc. vs Altimmune, Inc.
| Latest fiscal year | Annexon, Inc. ANNX | Tonix Pharmaceuticals Holding Corp. TNXP | Contineum Therapeutics, Inc. CTNM | Altimmune, Inc. ALT |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $13.11M | n/a | $41.0K |
| Revenue growth (YoY) | n/a | +29.8% | n/a | +105.0% |
| Gross margin | n/a | 49.3% (computed) | n/a | n/a |
| Operating margin | n/a | -959.1% | n/a | n/m |
| Net margin | n/a | -946.2% | n/a | n/m |
| Net income | -$206.69M | -$124.02M | -$59.98M | -$88.09M |
| EPS (Diluted) | -$1.34 | -$14.57 | -$2.17 | -$1.00 |
| Operating cash flow | -$186.36M | -$99.84M | -$55.31M | -$67.53M |
| Free cash flow | -$186.49M | -$103.21M | -$55.54M | -$67.55M |
| Cash & equivalents | $162.05M | $207.64M | $75.60M | $43.76M |
| Total assets | $277.57M | $277.17M | $276.64M | $279.93M |
| Total liabilities | $65.92M | $32.02M | $15.65M | $55.04M |
| Shareholders' equity | $211.65M | $245.15M | $260.99M | $224.89M |
| Return on year-end equity | -97.7% | -50.6% | -23.0% | -39.2% |
| Shares outstanding | 149.36M | 12.79M | n/a | 110.88M |
Revenue, most recent five fiscal years
| Fiscal year | Annexon, Inc. | Tonix Pharmaceuticals Holding Corp. | Contineum Therapeutics, Inc. | Altimmune, Inc. |
|---|---|---|---|---|
| Latest | n/a | $13.11M Ended 2025-12-31 | $0 Ended 2024-12-31 | $41.0K Ended 2025-12-31 |
| 1 year earlier | n/a | $10.09M Ended 2024-12-31 | $50.00M Ended 2023-12-31 | $20.0K Ended 2024-12-31 |
| 2 years earlier | n/a | $7.77M Ended 2023-12-31 | n/a | $426.0K Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | n/a | -$68.0K Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | n/a | $4.41M Ended 2021-12-31 |